



**JOINT FAO/WHO FOOD STANDARDS PROGRAMME
CODEX COMMITTEE ON RESIDUES OF VETERINARY DRUGS IN FOODS**

Twenty-first Session

Minneapolis, Minnesota, United States of America, 26 – 30 August 2013

The session will be held at the Hyatt Regency Minneapolis, 1300 Nicollet Mall, Minneapolis from Monday, 26 August at 9:30 hours to Friday, 30 August 2013

The meetings of the Working Groups will take place at the same venue

On Saturday, 24 August 2013, the Working Group on Risk Analysis Policy on Extrapolation of MRLs of Veterinary Drugs to Additional Species and Tissues MRLs will meet from 09:00 to 12:00; the Working Group on the Priority List of Veterinary Drugs Requiring Evaluation or Re-evaluation by JECFA will meet from 14:30 to 15:30; and the Working Group on the Concern Form” for the CCRVDF will meet from 15:30 to 17:00

On Sunday, 25 August 2013, the Working Group on Guidelines on Performance Characteristics for Multi-residues Methods will be held from 09:00 to 12:00 and the Working Group on Risk Management Recommendations for Residues of Veterinary Drugs for which no ADI and/or MRLs Working Group will be held from 14:00 to 17:00

PROVISIONAL AGENDA

Agenda Item	Subject Matter	Document Reference
1	Adoption of agenda	CX/RVDF 13/21/1
2	Matters referred by the Codex Alimentarius Commission and other Codex Committees and Task Forces	CX/RVDF 13/21/2
3	Matters arising from FAO/WHO and from the Joint FAO/WHO Expert Committee on Food Additives (JECFA)	CX/RVDF 13/21/3 CX/RVDF 13/21/3-Add.1 CX/RVDF 13/21/3-Add.2
4	Report of the OIE activities, including the harmonization of technical requirements for registration of veterinary medicinal products (VICH)	CX/RVDF 13/21/4
	<u>Maximum Residue Limits (MRLs) for veterinary drugs</u>	
5(a)	Draft MRLs for veterinary drugs (at Step 6)	REP12/RVDF App. V
	- Comments at Step 6 (replies to CL 2012/23-RVDF, Part A)	CX/RVDF 13/21/5 CX/RVDF 13/21/5-Add.1
5(b)	Proposed draft MRLs for Veterinary Drugs (at Step 4)	REP12/RVDF App. VI
	<u>Maximum Residue Limits (MRLs) for veterinary drugs</u>	
6	Risk Management Recommendations for Residues of Veterinary Drugs for which no ADI and/or MRLs has been recommended by JECFA due to Specific Human Health Concerns	CL 2012/23-RVDF, Part B CX/RVDF 13/21/6
	- Comments at Step 3	CX/RVDF 13/21/6 Add.1 CX/RVDF 13/21/6-Add.2

Agenda Item	Subject Matter	Document Reference
	<u>Methods of analysis for residues of veterinary drugs in foods</u>	CX/RVDF 13/21/6-Add.3
7	Proposed draft Guidelines on performance characteristics for multi-residues methods (Appendix to CAC/GL 71-2009) (N01-2011)	CX/RVDF 13/21/7
	• Comments at Step 3	CX/RVDF 13/21/7 Add.1
		CX/RVDF 13/21/7-Add.2
	<u>Risk Analysis Principles applied by the CCRVDF</u>	
8(a)	Risk Analysis Policy on Extrapolation of MRLs of Veterinary Drugs to Additional Species and Tissues (replies to CL 2012/11-RVDF, Part B, points 7 and 8)	CX/RVDF 13/21/8
		CX/RVDF 13/21/8-Add.1
		CX/RVDF 13/21/8-Add.2
8(b)	Proposed “concern form” for the CCRVDF (format and policy procedure for its use)	CX/RVDF 13/21/9
		CX/RVDF 13/21/9 Add.1
		CX/RVDF 13/21/9-Add.2
	<u>Priority list of veterinary drugs requiring evaluation or re-evaluation</u>	
9(a)	Draft priority list of veterinary drugs requiring evaluation or re-evaluation by JECFA (replies to CL 2012/30-RVDF)	CX/RVDF 13/21/10
9(b)	Database on countries’ needs for MRLs	CX/RVDF 13/21/11
	<u>Discussion papers</u>	
10	Discussion Paper on Guidelines on the Establishment of MRLs or other Limits in Honey	CX/RVDF 13/21/12
11	Other business and future work	
11(a)	Proposed amendments to the Terms of Reference of CCRVDF (replies to CL 2012/11-RVDF, Part B, point 6)	CX/RVDF 13/21/13
		CX/RVDF 13/21/13-Add.1
12	Date and place of next session	
13	Adoption of the report	

INFORMATION DOCUMENTS

Information document for support of the discussion on the MRLs for [RVDF/21 INF/01](#) veterinary drugs

NOTES ON THE PROVISIONAL AGENDA

Agenda Item 6: Appendices I and II to CL 2012/23-RVDF, working document CX/RVDF 13/21/6 and comments to these documents compiled in CX/RVDF 13/21/6 Add.1 in the physical Working Group on the Guidelines on Risk Management Recommendations for Residues of Veterinary Drugs for which no ADI and/or MRLs. The report of this Working Group will be made available as a CRD at the Session and will be considered under this item.

Agenda Item 7: Working document CX/RVDF 13/21/7 and comments to this document compiled in CX/RVDF 13/21/7 Add.1 will form the basis for discussion in the physical Working Group on the Guidelines on Performance Characteristics for Multi-residues Methods. The report of this Working Group will be made available as a CRD at the Session and will be considered under this item.

Agenda Item 8(a): Working document CX/RVDF 13/21/8 will be discussed at the physical Working Group on Risk Analysis Policy on Extrapolation of MRLs of Veterinary Drugs to Additional Species and Tissues MRLs. The report of this Working Group will be made available as a CRD at the Session and will be considered by the Committee under this item.

Agenda Item 8(b): Working document CX/RVDF 13/21/9 8 will be discussed at the physical Working Group on the "Concern form" for the CCRVDF. The report of this Working Group will be made available as a CRD at the Session and will be considered by the Committee under this item.

Agenda Item 9(a): Working document CX/RVDF 13/21/10 will be discussed at the physical Working Group on the Priority List of Veterinary Drugs Requiring Evaluation or Re-evaluation by JECFA. The report of this Working Group will be made available as a CRD at the Session and will be considered under this item.